Drug-use patterns and severe adverse events with disease-modifying drugs in patients with multiple sclerosis: a cohort study based on German claims data
Alexandra Simbrich,1 Jasmine Thibaut,1 Laura Khil,1,2 Klaus Berger,1 Oliver Riedel,3 Niklas Schmedt3,41Institute of Epidemiology and Social Medicine, University of Münster, 48149 Münster, Germany; 2Cancer Registry North Rhine-Westphalia, 44801, Bochum, Germany; 3Department of Clini...
Guardado en:
Autores principales: | Simbrich A, Thibaut J, Khil L, Berger K, Riedel O, Schmedt N |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/963d319a905840299a92bfc98e4d4865 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dermoscopic Aspects of Cutaneous Adverse Drug Reactions
por: Gabriela Rossi, et al.
Publicado: (2021) -
Epidemiology and costs of multiple sclerosis in Switzerland: an analysis of health-care claims data, 2011–2015
por: Blozik E, et al.
Publicado: (2017) - Multiple sclerosis clinical and laboratory research.
-
Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach
por: Hamdy SM, et al.
Publicado: (2020) -
The role and histopathology of oral drug challenge in the evaluation of fixed drug eruptions
por: Megan Brinkworth Vissing, et al.
Publicado: (2021)